Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study
| Autor: | Merrill J. Egorin, Gurkamal Chatta, Lisa L. von Moltke, Suresh Ramalingam, Michael D. Karol, William Riordan, Rachel Neuwirth, Michael R Cooper, Ramesh K. Ramanathan, William L. Trepicchio, Michael Rader, Eric X. Chen, Karthik Venkatakrishnan |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Antifungal Agents Antineoplastic Agents Pharmacology Drug Administration Schedule Bortezomib Pharmacokinetics Neoplasms hemic and lymphatic diseases medicine Humans Drug Interactions Pharmacology (medical) Prospective Studies Cross-Over Studies Dose-Response Relationship Drug business.industry Middle Aged Boronic Acids Crossover study Ketoconazole Area Under Curve Pyrazines Pharmacodynamics Concomitant Proteasome inhibitor Cytochrome P-450 CYP3A Inhibitors Drug Therapy Combination Female Median body business medicine.drug |
| Zdroj: | Clinical Therapeutics. 31:2444-2458 |
| ISSN: | 0149-2918 |
| DOI: | 10.1016/j.clinthera.2009.11.012 |
| Popis: | Background: The proteasome inhibitor bortezomib undergoes oxidative biotransformation via multiple cytochrome P450 (CYP) enzymes, with CYP3A4 identified as a partial, yet potentially important, contributor based on in vitro drug metabolism studies. Objective: The aim of this study was to assess the effect of concomitant administration of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of bortezomib. Methods: This was a prospective, multicenter, openlabel, randomized, multiple-dose, 2-way crossover study in patients with advanced solid tumors. All patients received bortezomib 1.0 mg/m2 IV (on days 1, 4, 8, and 11 of two 21-day cycles) and were randomized to receive concomitant ketoconazole 400 mg on days 6, 7, 8, and 9 of cycle 1 or 2. Serial blood samples were collected over the day-8 dosing interval (immediately prior to bortezomib administration, and from 5 minutes to 72 hours after administration) in cycles 1 and 2 for measurement of plasma bortezomib concentrations for noncompartmental PK analysis and blood 20S proteasome inhibition for PD analysis. All adverse events (AEs) were recorded during each cycle including serious AEs and all neurotoxicity events for up to 30 days after the last dose of bortezomib. Results: Twenty-one patients (median age, 57 years; sex, 67% male; race, 86% white; median body surface area, 2.01 m2) were randomized to treatment. Twelve pa- tients completed the protocol-specified dosing and PK sampling in both cycles 1 and 2. Assessment of the effect of ketoconazole on bortezomib PK and PD was based on data in these 12 PK-evaluable patients. The ratio of geometric mean bortezomib AUC0-tlast(AUC from time 0 to last quantifiable concentration) for bortezomib plus ketoconazole versus bortezomib alone was 1.352 (90% CI, 1.032–1.772). Consistent with this observed mean increase in bortezomib exposure, concomitant administration of ketoconazole was associated with a corresponding increase (24%–46%) in the blood proteasome inhibitory effect. Conclusion: Concomitant administration of the CYP3A inhibitor ketoconazole with bortezomib resulted in a mean increase of 35% in bortezomib exposure. ClinicalTrials.gov identifier: NCT00129207. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect